Korea's Economy Is on the Move: Semiconductor Boom, a New Fed Chair, and What It All Means

A Big Week for the Korean Economy

So here's the thing — a lot is happening all at once in the world of Korean economics, and it's actually more connected than it might first appear. You've got South Korea's central bank preparing to revise its growth forecast upward, a new U.S. Federal Reserve chair just settling into his seat, and Washington starting to raise serious alarms about Chinese biotech. Let's break it all down.

The Bank of Korea Is About to Get a Lot More Optimistic

The Bank of Korea — South Korea's central bank, comparable to the U.S. Federal Reserve — is expected to release its revised economic outlook on May 28. And if a survey of six top economic experts published by Yonhap News Agency is anything to go by, the numbers are going to look quite a bit rosier than before.

Back in February, the Bank of Korea had projected real GDP growth of 2.0% for 2025. Now, most experts surveyed expect that forecast to be bumped up to somewhere between 2.5% and 2.6% — a revision of at least half a percentage point. That might not sound dramatic, but in macroeconomic terms, that's a pretty significant upward shift.

What's driving it? In short: semiconductors, and the AI boom fueling demand for them.

The Semiconductor Story Behind the Numbers

South Korea's first quarter GDP growth came in at 1.7% quarter-on-quarter — almost double the Bank of Korea's own February estimate of 0.9%. A big reason for that surprise? Semiconductor exports. As global demand for AI servers and high-performance memory chips accelerates, Korean chipmakers are reaping the rewards, and that's rippling through the broader economy in production, capital investment, and the current account balance.

Park Jeong-woo, an economist at Nomura Securities Korea, said the strong Q1 performance combined with export momentum makes a large upward revision to the full-year forecast essentially unavoidable. Chang Min, a senior researcher at the Korea Institute of Finance, made an interesting point that sets this cycle apart from previous semiconductor booms: this one is structurally different because it's being driven by AI demand, not just a typical tech upgrade cycle. That means the upswing could last longer than usual.

Ahn Jae-gyun at Korea Investment Securities estimated that semiconductor exports alone accounted for roughly 35% of Korea's economic growth contribution in Q1, and suggested that as production volumes increase in the second half of the year, the impact could grow even further.

But There Are Clouds on the Horizon

Not everyone is breaking out the champagne just yet. Experts are also flagging a potential upward revision to inflation forecasts — from the current 2.2% estimate to somewhere in the 2.5% to 2.7% range. The culprits? Rising oil prices and a weaker won.

Joo Won, head of research at the Hyundai Research Institute, pointed to the risk of an oil price spike and even the possibility of Strait of Hormuz disruptions — a key chokepoint for global oil shipping — as factors that could push inflation higher than expected. Cho Young-moo of NH Financial Research noted that uncertainty remains high depending on how both the Iran situation and the semiconductor cycle play out.

What's really interesting here is the bind this creates for monetary policy. If both growth and inflation forecasts rise simultaneously, the Bank of Korea faces a tricky balancing act on interest rate decisions going forward.

A New Sheriff at the Fed — and What It Means for Korea

Adding another layer of complexity is what's happening in Washington. Kevin Warsh was officially sworn in as the new Chair of the U.S. Federal Reserve on May 22, taking over from Jerome Powell. The Fed, while a U.S. institution, effectively sets the tone for global financial markets — its decisions move the dollar, shake U.S. Treasury yields, and redirect capital flows in and out of emerging markets like South Korea.

Warsh isn't an unknown quantity. He served as a Fed governor during the 2008 global financial crisis, and notably left the institution in 2011 after voicing criticism of the second round of quantitative easing — the policy of printing money to stimulate the economy. That history means markets aren't treating him as a simple "dovish" (pro-low-interest) figure. He's harder to read than that.

In his inaugural remarks, Warsh emphasized price stability and maximum employment as the Fed's core mission, while also stressing independence and a reform-oriented approach. The signal being sent seems to be twofold: he won't simply bend to pressure from President Trump to cut rates, but he also plans to operate differently from the Powell era.

The Korean Won and the Dollar Pressure

For Korea, a Fed chair who is in no rush to cut rates — especially one who might keep monetary policy tighter for longer if inflation doesn't fully cool — is a challenge. Higher U.S. interest rates tend to strengthen the dollar, which puts pressure on the Korean won. The USD/KRW exchange rate has already been hovering near 1,520 won to the dollar, with Korean authorities signaling they'll take "decisive action if necessary."

A weaker won is a double-edged sword. Yes, it makes Korean exports more price-competitive internationally — and that helps the very semiconductor companies we were just talking about. But it also makes energy and raw material imports more expensive, feeding back into that inflation problem. Add geopolitical tensions in the Middle East to the mix, and you've got simultaneous pressure from both the exchange rate and oil prices.

Analysts in Seoul argue Korea needs to respond on three fronts: strengthening its foreign exchange reserves and liquidity buffers, doubling down on industrial competitiveness in AI, semiconductors, batteries, and shipbuilding, and — critically — maintaining the independence and credibility of the Bank of Korea itself. As one editorial framed it, the strength of a currency ultimately comes not from the interest rate number, but from the market's trust in the principles behind policy decisions.

U.S. Moves Against Chinese Biotech — A Window Opens for Korea?

Meanwhile, in a development that could quietly reshape the global pharmaceutical landscape, a senior U.S. lawmaker is pushing to cut American capital off from Chinese biotech companies — and South Korean pharma firms are watching closely.

Representative John Moolenaar, Chair of the House Select Committee on China, sent a letter on May 21 to Treasury Secretary Scott Bessent urging that biotech be added to the list of restricted sectors under the COINS Act — short for the Comprehensive Outbound Investment National Security Act. This law is designed to prevent U.S. capital from flowing into advanced technology sectors in adversarial nations.

The backdrop here is striking. The Korea Bio Association's BioEconomy Research Center noted that global licensing deals between multinational pharmaceutical companies and Chinese biotech firms reached approximately $136 billion last year. Even more eye-opening: in 2020, Chinese companies accounted for zero percent of major new drug licensing deals worldwide valued at over $50 million. Last year, that figure was 48%. That's an extraordinary rise in just five years.

Moolenaar's letter specifically called out a $15 billion deal between Bristol Myers Squibb and Chinese drugmaker Hengrui Pharmaceuticals as an example of U.S. capital and intellectual property flowing into China's biotech sector. He urged the Treasury to designate pharmaceutical IP, drug development platforms, clinical research capabilities, and biopharmaceutical manufacturing know-how as restricted categories.

Could Korean Biotech Fill the Gap?

For South Korea's pharmaceutical and biotech industry, this geopolitical shift carries real opportunity. Korean companies recorded a record-breaking 20 trillion won (roughly $14.5 billion) in overseas technology licensing deals last year. But here's the context that matters: China's comparable figure was over 10 billion won — a fraction of the scale Chinese firms are transacting at globally.

The gap is large, but the direction of travel matters. Heo Hye-min, an analyst at Kiwoom Securities, argued that Korea has built differentiated strengths in the global market — a long track record of partnerships and high levels of data reliability that set it apart from Chinese competitors. She expressed optimism that more major licensing deals, including with "NewCo" structures — a trend where large pharmaceutical companies spin off new entities to license drugs — would emerge in the second half of the year.

If U.S. regulations do tighten around Chinese biotech, global pharmaceutical companies will need alternative innovation partners. South Korea, with its growing pipeline of novel drug candidates and established research credibility, is well positioned to step into that space.

The Big Picture

What ties all of this together is that South Korea is navigating a genuinely complex moment. The semiconductor boom is real, and it's lifting the economic outlook in a meaningful way. But the external environment — a new, unpredictable Fed chair, dollar pressure, Middle East instability, and a shifting global biotech order — means none of this is a smooth ride. The revised Bank of Korea forecast on May 28 will be a key moment to watch. Expect the headline number to be good. The question is how long it can stay that way.

This article is based on reports from Ddaily, Seoul Economic Daily, Ajunews.